Atara Biotherapeutics (ATRA)

Executive Summary

Atara Biotherapeutics is a clinical-stage biotechnology company pioneering off-the-shelf, allogeneic T-cell immunotherapies, leveraging its Epstein-Barr Virus (EBV) T-cell platform. The company achieved landmark approval of EBVALLO™ (tabelecleucel) in Europe for EBV+ post-transplant lymphoproliferative disease (PTLD). However, recent setbacks include the termination of ATA3219 trials in lymphoma and withdrawal in lupus nephritis, casting uncertainty on its pipeline. Atara's current focus includes a Phase 1 trial evaluating cyclophosphamide plus CAR T cells for malignant pleural mesothelioma (MPM), with completion expected in September 2026. Financially, Atara has a modest valuation of ~$41M and limited commercial revenue, relying on milestone payments and potential approvals. The company's ability to secure US FDA approval for EBVALLO and advance earlier-stage programs will be critical for value creation.

Upcoming Catalysts (preview)

• Q3 2026FDA approval decision for tabelecleucel (EBVALLO) in EBV+ PTLD60% success
• Q4 2026Phase 1 data readout for cyclophosphamide + CAR T cells in malignant pleural mesothelioma30% success
• TBDPotential partnership or licensing deal for allogeneic T-cell platform40% success